Think tank and survey results inform current DCT landscape.
Two recent activities by ACRP offers insights into industry’s views on decentralized clinical trials (DCT). In a think tank convened in October, participants from a variety of clinical trial stakeholder groups, offered that lack of clarity around regulatory requirements is the leading barrier to adopting DCTs at the site level, as well as a lack of budget flexibility and the challenges of managing third-party vendors. Additionally, survey results released by ACRP revealed that on a site-level, DCT technology utilization lags behind other trial technologies, sites that use DCT elements spend more time on trial delivery activities, and personnel perceptions of DCT elements strongly influence DCT acceptance.
